Sugi Predict

Sugi Predict / Compounds / SCHEMBL5729043

SCHEMBL5729043

SCHEMBL5729043

COc1ccc([C@@H]2C[C@H]2N)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 15/20 1.00
▸ MAOB P27338 9/20 1.00
▸ MAOA P21397 7/20 1.00
▸ HTR2C P28335 2/20 0.59
▸ KCNH2 Q12809 3/20 0.54
▸ RCOR1 Q9UKL0 3/20 0.54
▸ KDM1B Q8NB78 1/20 0.54
▸ CYP2C19 P33261 4/20 0.52
▸ CYP2B6 P20813 3/20 0.52
▸ CYP1A2 P05177 2/20 0.52
▸ CYP2D6 P10635 2/20 0.52
▸ CYP2C9 P11712 2/20 0.52
▸ LMNA P02545 1/20 0.52
▸ CYP3A4 P08684 1/20 0.52
▸ HTR1A P08908 1/20 0.52
▸ ADRA2A P08913 1/20 0.52
▸ CYP2A6 P11509 1/20 0.52
▸ SLC6A2 P23975 1/20 0.52
▸ ADRA1A P35348 1/20 0.52
▸ DRD3 P35462 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7094099 1.00 KDM1A (1.00) KDM1AMAOBMAOAHTR2CKCNH2
SCHEMBL6755876 1.00 KDM1A (1.00) KDM1AMAOBMAOAHTR2CKCNH2
SCHEMBL18596475 1.00 KDM1A (1.00) KDM1AMAOBMAOAHTR2CKCNH2
Hydrochloric Acid SCHEMBL15091706 0.98 KDM1A (1.00) KDM1AMAOBMAOAHTR2CKCNH2
Hydrochloric Acid SCHEMBL15091705 0.98 KDM1A (1.00) KDM1AMAOBMAOAHTR2CKCNH2
SCHEMBL12971942 0.94 KDM1A (0.89) KDM1AMAOBMAOAHTR2CKCNH2
SCHEMBL11064726 0.84 KDM1A (0.72) KDM1AMAOBMAOAHTR2CSLC6A2
SCHEMBL11064728 0.84 KDM1A (0.72) KDM1AMAOBMAOAHTR2CSLC6A2
SCHEMBL4257203 0.80 KDM1A (0.67) KDM1AMAOBMAOAHTR2CSLC6A2
SCHEMBL4266649 0.80 KDM1A (0.67) KDM1AMAOBMAOAHTR2CSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4559902-A2 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE Imago Biosciences Inc. (US) 2025-05-28 — — EP disclosed
EP-3256218-B1 A KDM1A INHIBITOR AND ITS USE IN THERAPY IMAGO BIOSCIENCES INC (US) 2024-12-11 — — EP disclosed
US-11773068-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2023-10-03 — — US disclosed
US-11773068-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2023-10-03 — — US disclosed
US-11655226-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2023-05-23 — — US disclosed
US-11655226-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2023-05-23 — — US disclosed
US-20230080054-A1 INHIBITORS OF ANOCTAMIN 6 PROTEIN AND USES THEREOF ILDONG PHARMACEUTICAL CO., LTD. (KR) 2023-03-16 — — US disclosed
WO-2022195522-A1 INHIBITORS OF ANO6 AND THEIR USES THEREOF ILDONG PHARMACEUTICAL CO., LTD. (KR) 2022-09-22 — — WO disclosed
WO-2022157686-A1 INHIBITORS OF ANOCTAMIN 6 PROTEIN AND USES THEREOF ILDONG PHARMACEUTICAL CO., LTD. (KR) 2022-07-28 — — WO disclosed
CN-108779096-B Fluorine-substituted cyclopropylamine compounds, and preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2022-07-01 — — CN disclosed
US-6713483-B1 TREATING PLATELET AGGREGATION DISORDER ASTRAZENECA AB (SE) 2004-03-30 — — US disclosed
US-20040023988-A1 Novel compounds ASTRAZENECA AB (SE) 2004-02-05 — — US disclosed
EP-0996621-B1 TRIAZOLO[4,5-d]PYRIMIDINE DERIVATIVES AS ANTI-THROMBOTIC AGENTS ASTRAZENECA AB (SE) 2003-10-01 — — EP disclosed
EP-1232156-B1 [1,2,3]-TRIAZOLO[4,5-d]PYRIMIDINE DERIVATIVES AS ANTI-THROMBOTIC AGENTS ASTRAZENECA AB (SE) 2003-06-04 — — EP disclosed
EP-1296938-A1 CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE Pfizer Limited (GB) 2003-04-02 — — EP disclosed
EP-1056749-B1 NOVEL TRIAZOLO(4,5-d)PYRIMIDINE COMPOUNDS ASTRAZENECA UK LTD (GB) 2003-02-19 — — EP disclosed
US-20020052370-A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER, INC. 2002-05-02 — — US disclosed
US-6369064-B1 MYOCARDIAL INFARCTION AND UNSTABLE ANGINA; P2T-RECEPTOR ANTAGONISTS; ANTITHROMBOTIC AGENTS; 7-(SUBSTITUTED AMINO) -5-(THIO)-3H-1,2,3-TRIAZOLO(4,5-D)PYRIMIDIN-3-YL) -CYCLOPENTANECARBOXAMIDES ASTRAZENECA AB (SE) 2002-04-09 — — US disclosed
WO-2002002513-A1 CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE PFIZER LIMITED (GB) 2002-01-10 — — WO disclosed
US-6251910-B1 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists ASTRAZENECA UK LIMITED (GB) 2001-06-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230080054-A1 INHIBITORS OF ANOCTAMIN 6 PROTEIN AND USES THEREOF ANO1, ANO2, CACYBP KDM1A 3718/4885MAOB 3597/4885MAOA 3365/4885
US-20020052370-A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase ENGASE, ENPEP, CPN1 KDM1A 1587/4885MAOB 544/4885MAOA 383/4885
US-20040023988-A1 Novel compounds DPYD, TYMP, TYMS KDM1A 2172/4885MAOB 2153/4885MAOA 2742/4885
US-11773068-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A KDM1A 2/4885MAOB 3325/4885MAOA 3580/4885
US-11655226-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A KDM1A 2/4885MAOB 3325/4885MAOA 3580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.